Provided by Tiger Fintech (Singapore) Pte. Ltd.

Can Fite Biofarma

1.20
-0.0300-2.44%
Post-market: 1.200.00000.00%19:53 EDT
Volume:349.49K
Turnover:427.01K
Market Cap:15.42M
PE:-1.10
High:1.27
Open:1.27
Low:1.18
Close:1.23
Loading ...

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

GlobeNewswire
·
17 Apr

Can Fite Biopharma Ltd : Alliance Global Partners Cuts Target Price to $4.5 From $12

THOMSON REUTERS
·
15 Apr

Can-Fite price target lowered to $4.50 from $12 at Alliance Global Partners

TIPRANKS
·
15 Apr

Amex Halt News Pending Lst 1.595000

THOMSON REUTERS
·
15 Apr

Can-Fite BioPharma announces $3.0M registered direct offering of ADSs

TIPRANKS
·
15 Apr

Can-Fite BioPharma Projects $685 Million in Future Revenue via Collaborations

MT Newswires Live
·
15 Apr

Can-Fite BioPharma trading halted, news pending

TIPRANKS
·
15 Apr

Amex Halt News Pending Lst 1.595000

THOMSON REUTERS
·
15 Apr

Can-Fite BioPharma announces completion of analysis of current partnerships

TIPRANKS
·
14 Apr

Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships

GlobeNewswire
·
14 Apr

Can-Fite BioPharma FY24 Net Loss $7.88M

Benzinga
·
14 Apr

Press Release: Can-Fite Reports 2024 Financial Results and Clinical Update

Dow Jones
·
14 Apr

bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESS Newswire
·
28 Mar

Can-Fite BioPharma initiates Phase 3 psoriasis study of piclidenoson

TIPRANKS
·
26 Mar

Can-Fite BioPharma Begins Late-Stage Study of Prospective Psoriasis Medication

MT Newswires Live
·
24 Mar

Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
20 Mar

Can-Fite Says US FDA Approves Compassionate Use Treatment With Namodenoson in Pancreatic Cancer Patient

MT Newswires Live
·
18 Mar

Can-Fite announces FDA approved compassionate use treatment of Namodenoson

TIPRANKS
·
18 Mar

Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient

GlobeNewswire
·
18 Mar

Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
03 Mar